Dog cancer treatment ImpriMed aims to expand its AI technology into human oncology

ImpriMed, a precision medicine startup, has developed AI-powered technology for personalized drug efficacy prediction in canine and feline blood cancers. The company now aims to expand its technology to human oncology applications. ImpriMed recently closed a $23 million Series A funding and has been partners with SK Telecom. Their B2B service involves collecting live cancer cells and blood samples from patients and using AI to predict effective anticancer drugs. The company is also working on expanding its precision oncology services for human patients, aiming to commercialize its AI software for multiple myeloma and other services for human cancers. They successfully demonstrate improved treatment outcomes through their services and have unique strength in developing and incorporating AI models into personalized medicine services.